IL18 and hyperinsulinemic hypoglycemia, familial, 4: A phase III, double-blinded placebo-controlled clinical trial using IL-18 BP (tadekinig alpha) is currently evaluating the efficacy and tolerability of IL-18BP in IL-18 driven autoinflammatory conditions including NLRC4 associated hyperinflammation and XIAP deficiency (NCT03113760).